Essential medicines for noncommunicable diseases: “Quality variable”

Noncommunicable diseases.

From the Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston (D.J.H.); the Public Health Foundation of India, New Delhi (K.S.R.); and the World Heart Federation, Geneva (K.S.R.). Address reprint requests to Dr. Hunter at the Departments of Epidemiology and Nutrition, Harvard School of Public Health, 677 Huntington Ave., Boston, MA 02115, or at [email protected]...

Rare essentials: drugs for rare diseases as essential medicines.

Since 1977, the WHO Model List of Essential Medicines (EML), published by WHO, has provided advice for Member States that struggle to decide which pharmaceutical technologies should be provided to patients within their public health systems. Originating from outside WHO, an incentive system has been put in place by various governments for the development of medicines for rare diseases ("orphan ...

Overcoming Obstacles To Enable Access To Medicines For Noncommunicable Diseases In Poor Countries.

The modern access-to-medicines movement grew largely out of the civil-society reaction to the HIV/AIDS pandemic three decades ago. While the movement was successful with regard to HIV/AIDS medications, the increasingly urgent challenge to address access to medicines for noncommunicable diseases has lagged behind-and, in some cases, has been forgotten. In this article we first ask what causes th...

Essential Medicines for Children: An Endocrine Perspective

10 . Noncommunicable diseases and prisoners

Key points • The global burden of and threat from noncommunicable diseases (NCDs) constitute a major public health challenge that undermines social and economic development throughout the world. Prisoners are at greater risk for such diseases. • Most information on NCDs in prisoners comes from high-income countries despite the fact that globally, 80% of these deaths from these diseases are in l...